Literature DB >> 30266353

Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018.

Hanno H Leuchte1, Henrik Ten Freyhaus2, Henning Gall3, Michael Halank4, Marius M Hoeper5, Harald Kaemmerer6, Christian Kähler7, Gabriela Riemekasten8, Silvia Ulrich9, Martin Schwaiblmair10, Ralf Ewert11.   

Abstract

In the summer of 2016, delegates from the German Respiratory Society, the German Society of Cardiology and the German Society of Pediatric Cardiology met in Cologne, Germany, to define consensus-based practice recommendations for the management of patients with pulmonary arterial hypertension (PAH). These recommendations were built on the 2015 European Pulmonary Hypertension guidelines and included new evidence, where available, and were last updated in the spring of 2018. This article focusses on the proposed risk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH), covering 3 parts: In part 1, methods and markers that are recommended to assess severity and progression of PAH are discussed and commented. These updated comments incorporate most recent data as well as challenges arising from the variability of phenotypes of PAH patients with increasing cardiopulmonary comorbidities. In part 2, the proposed ESC/ERS risk stratification strategy is discussed, together with a review of the recent validation studies from different European registries. Finally, in part 3, the working group of the Cologne Consensus Conference provides recommendations on how risk assessment may be implemented in routine clinical practice and may serve clinical decision making.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Pulmonary hypertension; Registries; Risk assessment; Validation

Mesh:

Year:  2018        PMID: 30266353     DOI: 10.1016/j.ijcard.2018.08.084

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  14 in total

1.  Diagnostic and prognostic value of right ventricular eccentricity index in pulmonary artery hypertension.

Authors:  Lili Wang; Xiaoling Chen; Ke Wan; Chao Gong; Weihao Li; Yuanwei Xu; Jie Wang; Juan He; Bi Wen; Yuchi Han; Rui Zeng; Yucheng Chen
Journal:  Pulm Circ       Date:  2020-04-09       Impact factor: 3.017

2.  Postpartum pulmonary circulation in pregnant rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  He Jing; Mu Jin; Yue Li; Yuwei Sun; Jiakai Lu; Weiping Cheng
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

Review 3.  Preoperative Assessment and Perioperative Management of the Patient with Pulmonary Vascular Disease.

Authors:  Jochen Steppan; Paul M Heerdt
Journal:  Clin Chest Med       Date:  2021-01-08       Impact factor: 2.878

4.  Heart rate variability in pulmonary hypertension with and without sleep apnea.

Authors:  Carolina Gonzaga Carvalho; Richard Bresler; Ying Xuan Zhi; Hisham Alshaer; John T Granton; Clodagh M Ryan
Journal:  Heliyon       Date:  2019-07-03

Review 5.  Practical management of riociguat in patients with pulmonary arterial hypertension.

Authors:  Michael Halank; Kristin Tausche; Ekkehard Grünig; Ralf Ewert; Ioana R Preston
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

6.  The six-transmembrane protein Stamp2 ameliorates pulmonary vascular remodeling and pulmonary hypertension in mice.

Authors:  Mehreen Batool; Eva M Berghausen; Mario Zierden; Marius Vantler; Ralph T Schermuly; Stephan Baldus; Stephan Rosenkranz; Henrik Ten Freyhaus
Journal:  Basic Res Cardiol       Date:  2020-11-13       Impact factor: 17.165

7.  Risk assessment in precapillary pulmonary hypertension: a comparative analysis.

Authors:  Thomas Sonnweber; Eva-Maria Schneider; Manfred Nairz; Igor Theurl; Günter Weiss; Piotr Tymoszuk; Judith Löffler-Ragg
Journal:  Respir Res       Date:  2021-01-21

8.  miR-1226-3p Promotes eNOS Expression of Pulmonary Arterial Endothelial Cells to Mitigate Hypertension in Rats via Targeting Profilin-1.

Authors:  Jie Jian; Liang Xia
Journal:  Biomed Res Int       Date:  2021-11-03       Impact factor: 3.411

9.  FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

Authors:  Meibin Wang; Lihuang Su; Junwei Sun; Luqiong Cai; Xiuchun Li; Xiayan Zhu; Lanlan Song; Jingyin Li; Shuolan Tong; Qinlian He; Mengsi Cai; Lehe Yang; Yanfan Chen; Liangxing Wang; Xiaoying Huang
Journal:  J Cell Mol Med       Date:  2022-01-06       Impact factor: 5.295

10.  Echocardiographic assessment of pulmonary arterial capacitance predicts mortality in pulmonary hypertension.

Authors:  Alexander Papolos; Geoffrey H Tison; Jacob Mayfield; Elena Vasti; Teresa DeMarco
Journal:  J Cardiol       Date:  2020-11-04       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.